Shenzhen Forward Pharmaceuticals Co. Ltd. has disclosed fibroblast growth factor receptor 2 (FGFR2) inhibitors reported to be useful for the treatment of cancer.

Beigene Ltd. has identified IL-17A/IL-17 receptor A (IL-17RA) interaction inhibitors reported to be useful for the treatment of cancer, psoriasis, rheumatoid arthritis, spondyloarthritis and multiple sclerosis.

St. Jude Children’s Research Hospital has described pregnane X receptor (PXR) modulators reported to be useful for the treatment of cancer.

Virginia Commonwealth University has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of traumatic brain injury, myocardial infarction, arthritis, diabetes, gout, COVID-19, Alzheimer’s and Parkinson’s disease, among others.

Blueprint Medicines Corp. has identified KIT (c-KIT) (mutant) inhibitors reported to be useful for the treatment of gastrointestinal stromal tumors (GIST).

Kumquat Biosciences Inc. has synthesized son of sevenless homolog 1 (SOS1)/GTPase KRAS interaction inhibitors reported to be useful for the treatment of cancer.

Proxygen GmbH has disclosed molecular glue degraders comprising a cullin-ring E3 ligase (CRL) binding moiety acting as cyclin-dependent kinase 12 (CDK12)/cyclin K degradation inducers. They are reported to be useful for the treatment of metabolic diseases, cancer, infections and more.

Mindset Pharma Inc. has described indoline derivatives acting as 5-HT2A receptor agonists reported to be useful for the treatment of anhedonia, anorexia nervosa, epilepsy, fragile X syndrome, obsessive-compulsive disorder, post-traumatic stress, stroke and Alzheimer’s disease, among others.

Rome Therapeutics Inc. has divulged didehydro-3’-deoxy-4’-ethynylthymidines acting as LINE-1 retrotransposable element ORF1 protein (L1RE1) and/or HERV-K reverse transcriptase inhibitors reported to be useful for the treatment of cancer, autoimmune disease and neurological disorders.

Nimbus Clotho Inc. has identified CTP synthase 1 (CTPS1) inhibitors reported to be useful for the treatment of psoriasis, lichen planus, lupus nephritis, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, autoimmune lymphoproliferative syndrome, and graft-vs.-host disease.